[Successful fibrinolytic therapy of early diagnosed coumarin necrosis]

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

ESMO gastrointestinal oncology·2026

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

ESMO real world data and digital oncology·2026

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.

ESMO open·2025

COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.

ESMO open·2022

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.

ESMO open·2021

[75-year old female with progressive idiopathic lung fibrosis].

Medizinische Klinik (Munich, Germany : 1983)·2011

[Mesenterial lymphangiolipoma - a rare finding in an asymptomatic patient].

Medizinische Klinik (Munich, Germany : 1983)·2011

[Resistant hypertension despite nine different antihypertensive drugs?].

Medizinische Klinik (Munich, Germany : 1983)·2011

[From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].

Medizinische Klinik (Munich, Germany : 1983)·2011

[Memorandum III "methods for health services research", Part 1 [authors: H. Pfaff, G. Glaeske, E. A. M. Neugebauer, M. Schrappe] and Part 2 [authors: E. A. M. Neugebauer, A. Icks, M. Schrappe] of the Deutsches Netzwerk Versorgungsforschung e.V.: A summary].

Medizinische Klinik (Munich, Germany : 1983)·2011

[Pulmonary affection in advanced liver disease - hepatepulonary syndrome and portopulmonary hypertension].

Medizinische Klinik (Munich, Germany : 1983)·2011

Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma.

medRxiv : the preprint server for health sciences·2026

Mitochondrial rewiring supports survival of triple negative breast cancer cells after ionizing radiation.

bioRxiv : the preprint server for biology·2026

A mammary-specific microfluidic device for studying post-radiotherapy vascular-immune cell interactions.

bioRxiv : the preprint server for biology·2026

Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer.

bioRxiv : the preprint server for biology·2026

Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations.

Frontiers in oncology·2026

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis.

medRxiv : the preprint server for health sciences·2026

Related Experiment Videos

[Successful fibrinolytic therapy of early diagnosed coumarin necrosis]

Related Concept Videos

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.

COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.

[75-year old female with progressive idiopathic lung fibrosis].

[Mesenterial lymphangiolipoma - a rare finding in an asymptomatic patient].

[Resistant hypertension despite nine different antihypertensive drugs?].

[From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].

[Memorandum III "methods for health services research", Part 1 [authors: H. Pfaff, G. Glaeske, E. A. M. Neugebauer, M. Schrappe] and Part 2 [authors: E. A. M. Neugebauer, A. Icks, M. Schrappe] of the Deutsches Netzwerk Versorgungsforschung e.V.: A summary].

[Pulmonary affection in advanced liver disease - hepatepulonary syndrome and portopulmonary hypertension].

Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma.

Mitochondrial rewiring supports survival of triple negative breast cancer cells after ionizing radiation.

A mammary-specific microfluidic device for studying post-radiotherapy vascular-immune cell interactions.

Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer.

Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations.

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis.

Related Experiment Videos

[Successful fibrinolytic therapy of early diagnosed coumarin necrosis]

Related Concept Videos

Related Articles